News and updates — Page 25 of 29 — German Market Access

First COVID-19 drug has been assessed by G-BA

The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It

If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,

This question was discussed at the recent G-BA meeting on 2 September 2021. Previously, the G-BA had decided on the following procedural

Did you know that some hospital methods are not covered by SHI funds? In Germany, non-drug interventions are assessed as methods. Methods

The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,